This document provides information about oral contraceptives, including how they work to prevent pregnancy, types of oral contraceptives, emergency contraception, side effects and drug interactions. It discusses both combined oral contraceptives containing estrogen and progesterone, as well as progestin-only pills. Emergency contraceptive pills containing levonorgestrel are described as well as long acting injectable and implantable progestin-only methods. Warnings and instructions regarding proper use and storage are also summarized.
the presentation includes a definition of oral contraceptives, type of oral contraceptives, detail description of both types with its mode of action and potential beneficial and unwanted effects also include pharmacokinetics of oral contraceptives and knowledge of emergency contraceptives
Birth control pills (oral contraceptives) are prescription medications that prevent pregnancy.
Birth control (contraceptive) medications contain hormones (estrogen and progesterone, or progesterone alone).
Combined pill ,phased pill, post cotal pilla and mini pill.
Advantages and disadvantages with a note on adverse effects and contraindications of oral contraceptives with a note synthetic agents.
the presentation includes a definition of oral contraceptives, type of oral contraceptives, detail description of both types with its mode of action and potential beneficial and unwanted effects also include pharmacokinetics of oral contraceptives and knowledge of emergency contraceptives
Birth control pills (oral contraceptives) are prescription medications that prevent pregnancy.
Birth control (contraceptive) medications contain hormones (estrogen and progesterone, or progesterone alone).
Combined pill ,phased pill, post cotal pilla and mini pill.
Advantages and disadvantages with a note on adverse effects and contraindications of oral contraceptives with a note synthetic agents.
These slides contain the information about Estrogen, its basic pharmacology, its synthesis in human body, Functions of estrogen, role in female puberty, Agonists of estrogen and antagonists of estrogen, also contain detail of the receptors associated with the estrogen functioning.
These slides contain the information about Estrogen, its basic pharmacology, its synthesis in human body, Functions of estrogen, role in female puberty, Agonists of estrogen and antagonists of estrogen, also contain detail of the receptors associated with the estrogen functioning.
A slight description on contraception, its types along with a brief explanation on Oral Contraceptives. Types of oral contraceptives, it's types, mechanism of action, contraindications, dosing, advantages, disadvantages, risk, benefit amd recent research trends.
methods used as contraception include guidelines, contraindications, side effects, and effectiveness.
intrauterine devices
condoms
diaphragm/cervical cap
cervical sponge
spermicide
progestrone only bills ( in the different froms)
combined hormonal therapy
emergency contraception
Hormonal contraception (Combined Hormonal Contraceptives)Naji Majid Ahmed
Combined Hormonal Contraceptives :
includes:
Combined Oral Contraceptives (Pills)
Contraceptive vaginal ring
Transdermal patch
2. Progestogen Only Contraceptions(POC):
includes:
Progestogen-only pill(POP)
Implant
Progestogen-only injectable
Progestogen-releasing intrauterine system(LNG–IUS)
Missed pills:
If one pill is missed, anywhere in the pack (ie more than 24 and up to 48 hours late):
The last pill missed should be taken now, even if it means taking two pills in one day.
The rest of the pack should be taken as usual.
No additional contraception is needed.
The seven-day break is taken as normal.
Emergency contraception is not needed if just one pill has been missed. However, it should be considered if other pills have been missed recently, either earlier in the current packet, or at the end of the previous packet.
Missed pills:
If two or more pills are missed (ie more than 48 hours late):
The last pill missed should be taken now, even if it means taking two pills in one day.
Any earlier missed pills should be left.
The rest of the pack should be taken as usual and additional precautions (eg, condoms or abstinence) should be taken for the next seven days.
The next step then depends on where in the packet the pills are missed:
The next step then depends on where in the packet the pills are missed:
If the pills are missed in the first week of a pack (pills 1-7): emergency contraception should be considered if the patient had unprotected sex in the pill-free interval or the first week of the pill packet. She should finish the packet and have the usual pill-free interval.
If the pills are missed in the second week of a pack (pills 8-14): there is no need for emergency contraception as long as the pills in the preceding seven days have been taken correctly. The packet should be finished and the usual pill-free interval taken.
If the pills are missed in the third week of a pack (pills 15-21): the next pack of pills should be started without a break - ie the pill-free interval is omitted. If taking a packet with dummy/placebo pills, these should be discarded, and the new packet started. Emergency contraception is not required.
If more than seven pills are missed, the woman should start again as if starting for the first time. (Exclude pregnancy, and start a new pack on the first day of the next menstrual period.)
oral contraceptive , definition , before prescribing it , how to use other uses , products in the pharmacy , side effects , drug interactions , contraindications .
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
2. Contents:-
Definition
From fertilization to implantation
Oral contraceptives
How birth control medication works
How to choose the drug
Types of oc’s
Available drugs
Emergency hormonal contraception
Drug interactions
Side effects
Warning
Over dose
Missed dose
Storage.
3. DEFINITION:-
Oral contraceptives are medicines
taken by mouth to help
prevent pregnancy.
They are also known as “birth
control pills”.
5. ORAL
CONTRACEPTIVES:-
Birth control pills (oral contraceptives) are
prescription
medications that prevent pregnancy.
Birth control (contraceptive) medications contain
hormones (estrogen and progesterone, or
progesterone alone).
Birth control pills may also be prescribed to reduce
menstrual cramps or prevent anemia.
Some women experience various levels of side effects
of birth control pills.
6. HOW BIRTH CONTROL MEDICATION
WORK:-
Hormonal birth control medications prevent pregnancy
through
the following ways:
By blocking ovulation (release of an egg from the ovaries), thus
preventing pregnancy
By altering mucus in the cervix, which makes it hard for sperm
to
travel further
By changing the endometrium (lining of the uterus) so that it
cannot support a fertilized egg
By altering the fallopian tubes (the tubes through which eggs
move
from the ovaries to the uterus) so that they cannot effectively
move eggs toward the uterus
7.
8. AVAILABLE DOSAGE FORMS:-
Birth control (contraceptive) medications contain
hormones (estrogen and progesterone, or
progesterone alone).
The medications are available in various forms, such as
pills, injections (into a muscle), topical (skin)
patches, and slow-release systems (vaginal rings,
skin implants, and contraceptive-infused intrauterine
devices
9. HOW TO CHOOSE THE DRUG?
Choosing which estrogen and progesterone dose, type, and
administration method is
Highly patient specific, meaning that the choice greatly
depends on factors unique to an individual.
General goals are to choose a product that provides good
menstrual cycle control with the fewest adverse (side)
effects and to use the lowest hormone dose possible.
After beginning birth control medications, it may be
necessary to adjust the dose or to choose a different
product.
10. TYPES OF ORAL CONTRACEPTIVES:-
THE COMBINED PILL
THE PROGESTOGEN ONLY PILL
11. Formulations may be :
1. Monophasic (each tablet contains a fixed
amount of estrogen and progestin);
2. Biphasic (each tablet contains a fixed
amount of estrogen, while the amount of progestin
increases in the second half of
the cycle); or
3. Triphasic (the amount of estrogen may be
fixed or variable, while the amount of progestin
increases in 3 equal phases).
The combined pill
(combinations of an oestrogen with a
progestogen)
12. The combined pill
(combinations of an oestrogen with a
progestogen)
The oestrogen in most combined preparations(second-
generation pills) is ethinylestradiol,although a few
preparations contain mestranol instead.
The progestogen may be norethisterone,levonorgestrel,
ethynodiol, or-in 'thirdgeneration‘ pills-desogestrel or
gestodene,which are more potent, have less androgenic
action and cause less change in lipoprotein metabolism,
but which probably cause a greater risk of
thromboembolism than do secondgeneration preparations.
13. The combined pill:-
The oestrogen content is generally 20-50μg of
ethinylestradiol or its equivalent, and a preparation is
chosen with the lowest oestrogen and progestogen
content that is well tolerated and gives good cycle
control in the individual woman.
This combined pill is taken for 21 consecutive days
followed by 7 pill-free days, which causes a withdrawal
bleed. Normal cycles of menstruation usually
commence fairly soon after discontinuing treatment.
14. MODE OF ACTION:-
oestrogen inhibits secretion of FSH via negative feedback
on the anterior pituitary, and thus suppresses development
of the ovarian follicle progestogen inhibits secretion of LH
and thus prevents ovulation; it also makes the cervical
mucus less suitable for the passage of sperm.
oestrogen and progestogen act in concert to alter the
endometrium in such a way as to discourage implantation.
They may also interfere with the coordinated contractions
of cervix, uterus and fallopian tubes that facilitate
fertilisation and implantation.
15.
16. The progestogen-only pill:-
The drugs used in progestogen only pills include
norethisterone, levonorgestrel or ethynodiol.
The pill is taken daily without interruption.
17. MODE OF ACTION:-
The mode of action is primarily on the cervical mucus,
which is made inhospitable to sperm. The progestogen
probably also hinders implantation through its effect
on the endometrium and on the motility and
secretions of the fallopian tubes
19. HORMONE CONTAINING
CONTRACEPTIVES:-
Combination contraceptives, that is,contraceptive
medications containing both estrogen and
progesterone, are the most effective means for
contraception with the exception of surgical
sterilization.
Several types of combination birth control pills exist,
including monophasic pills, biphasic pills,triphasic
pills, and 91-day-cycle pills.
20. MONOPHASIC PILLS:-
Monophasic pills have a constant dose of both
estrogen and progestin in each of the hormonally
active pills throughout the entire cycle (21 days of
ingesting active pills).
Several of the brands listed above may be available in
several strengths of estrogen or progesterone, from
which doctors choose according to a woman’s
individual needs.
21. BI-PHASIC PILLS:-
Biphasic pills typically contain 2 different progesterone
doses. The progesterone dose is increased about
halfway through the cycle.
TRIPHASIC PILLS:-
Triphasic pills gradually increase the dose of
estrogen during the cycle (some pills also increase
the progesterone dose).
Three different increasing pill doses are contained
in each cycle.
22. EMERGENCY HORMONAL
CONTRACEPTION:-
Levonelle 1500 (one step)
Contains high dose progesterone (levonorgesterel)
One 1500mcg tablet taken as soon as possible after
unprotected intercourse (up to 72 hours after)
Preferably within 12 hours, no later than 72 hours.
23. HOW DOES EHC WORKS:-
Dependent on point in the menstrual cycle
Either prevents or delays ovulation, prevents
fertilisation or prevents implantation of the fertilised
egg into the uterus.
Clinical opinion is that EHC is not an abortifacient
24. NINETY ONE DAY BIRTH CONTROL PILLS:-
These pills are monophasic birth control pills that have
been approved for use on a daily basis for 84 days
without interruption.
Users have fewer scheduled menstrual cycles (only 1
period every 3 months).
Data from clinical trials show that many women,
especially in the first few cycles of use, have more
unplanned bleeding and spotting between the
expected menstrual periods than women taking
conventional combination birth control pills.
25. LONG ACTING, INJECTABLE, PROGESTERONE ONLY
CONTRACEPTIVES:-
Medroxyprogesterone acetate (Depo-Provera)
Use:
The first injection is given within 5 days following the onset of
menstruation.
After that, an injection is needed every 11-13 weeks.
Side effects:
Since progesterone is the only hormonal ingredient, estrogen-
related side effects are avoided.
A side effect unique to this method of birth control is that most
women eventually stop having their periods.
Depo-Provera may last in the body for several months in women
who have used it on a long-term basis and can actually delay the
return to fertility after stopping the drug.
Approximately 70% of former users desiring pregnancy conceive
within 12 months, and 90% of former users conceive within 24
months. Other side effects include weight gain and depression.
26. TOPICAL CONTRACEPTIVE PATCH:-
Norelgestromin/ethinyl estradiol (Ortho Evra)
The topical patch may be applied to clean, dry skin on the shoulders, upper arms,
buttocks, or abdomen.
It should not be applied to red or inflamed areas of the skin or in areas where tight
clothing may rub.
The patch may be less effective in women weighing more than 198 pounds(90 kg).
Use:
A new patch is applied on the same day of the week, each week for 3 weeks in a row.
The first patch is applied either on the first day of the menstrual period or on the Sunday
following menses.
On the fourth week, no patch is applied.
Menstruation should begin during this time.
This 4-week period is considered 1 cycle.
Another 4-week cycle is started by applying a new patch following the 7-day
patch-free period.
27. SIDE EFFECTS:-
Side effects are similar to other birth control agents
containing both estrogen and progesterone.
Effects include menstrual irregularities,weight gain,
and mood changes.
Other specific side effects include a skin reaction at the
site of application and problems with contact use
28. WHY SHOULD NOT USE THESE MEDICATIONS:-
Women with the following conditions should not use estrogen
containing
birth control medications:
Allergy to any component of the product
History of blood clot disorders
History of stroke or heart attack
Heart valve disease with complications
Severe hypertension
Diabetes that causes blood vessel problems
Poorly controlled diabetes
Unexplained abnormal bleeding from the uterus
Jaundice during pregnancy or jaundice with prior hormonal
contraceptive use
29. DRUG INTERACTIONS:-
Certain drugs can decrease the effectiveness of
combination-type birth control pills by decreasing the drug
concentration in your system (impaired enterohepatic
recirculation or hepatic induction). This can result in
pregnancy.
Drugs that may cause this effect include: many
antibiotics(e.g., cephalosporins, chloramphenicol,
macrolides, penicillins, tetracyclines, sulfas), aprepitant,
bexarotene, bosentan, dapsone, griseofulvin, certain HIV
protease inhibitors (e.g., amprenavir, nelfinavir, ritonavir),
modafinil, nevirapine, rifamycins (e.g., rifampin), many
seizure medications (e.g., barbiturates, carbamazepine,
phenytoin, primidone, topiramate), St. John's wort.
30. DRUG INTERACTIONS:-
Before using this medication, tell your doctor or pharmacist of
all prescription and non-prescription/herbal medications you
may use, especially of: thyroid hormone drugs, certain
benzodiazepines (e.g.,diazepam, chlordiazepoxide), prednisone-
like drugs, certain antidepressants (e.g., tricyclics), beta-blockers
(e.g., metoprolol), "blood thinners" (anticoagulants such as
warfarin), insulin.
This product can affect the results of certain lab tests (e.g.,
thyroid).Inform all laboratory personnel that you use this drug.
Birth control pills may significantly intensify the effects of
alcohol.
Consult your doctor or pharmacist about this. Do not start or
stop any medicine without doctor or pharmacist approval.
31. SIDE EFFECTS:-
Nausea, breast tenderness, fluid retention,
weight gain, acne, breakthrough bleeding,
missed periods, headaches, depression, anxiety,
change in vision, other mood changes, and
lower sexual desire.
Additionally, the following more serious side
effects may occur:
Thromboembolism (blood clots)
Breast cancer
Cervical cancer
Benign liver tumors
Diabetes
32. WARNING:-
Smoking cigarettes while using this medication
increases your chance of having heart problems.
Do not smoke while using this medication.
The risk of heart problems increases with
age(especially in women greater than 35 years of age)
and with frequent smoking (15 cigarettes per day or
greater).
33. OVER DOSE:-
If overdose is suspected, contact your local poison
control center or emergency room immediately.
Symptoms of overdose may include nausea and
vomiting.
Females may experience vaginal bleeding.
34. MISSED DOSE:-
Missed dose advice differs and depends on the brand
used, and the number of doses missed.
Refer to the product package information for advice on
missed doses. Ask your doctor or pharmacist if you
have any questions.
35. STORAGE:-
Store at room temperature between 59 and 86 degrees
F (between 15 and 30 degrees C) away from moisture
and sunlight.
Do not store in the bathroom.